Future of Liver Transplantation

Without social change or new therapies, alcohol-associated liver disease (ALD) and metabolic dysfunction–associated steatotic liver disease (MASLD; formerly called nonalcohol-related fatty liver disease) will likely

Read More »

FGF21 Analogue Pegozafermin in NASH

The long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue pegozafermin improved fibrosis in a phase 2b trial of patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH). “These

Read More »

Upadacitinib for Crohn’s Disease

In patients with moderate-to-severe Crohn’s disease, the oral selective Janus kinase (JAK) inhibitor upadacitinib was superior to placebo when used for induction and maintenance treatment,

Read More »